| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Javier Fernández-Ruiz, Julián Romero, Guillermo Velasco, Rosa M Tolón, José A Ramos, Manuel Guzmá. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends in pharmacological sciences. vol 28. issue 1. 2007-03-22. PMID:17141334. |
cannabinoid cb2 receptor: a new target for controlling neural cell survival? |
2007-03-22 |
2023-08-12 |
Not clear |
| Cristina Benito, Juan Pablo Romero, Rosa María Tolón, Diego Clemente, Fabián Docagne, Cecilia J Hillard, Camen Guaza, Julián Romer. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 9. 2007-03-19. PMID:17329437. |
cannabinoid cb1 and cb2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. |
2007-03-19 |
2023-08-12 |
human |
| Cristina Benito, Juan Pablo Romero, Rosa María Tolón, Diego Clemente, Fabián Docagne, Cecilia J Hillard, Camen Guaza, Julián Romer. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 9. 2007-03-19. PMID:17329437. |
however, most experimental data come from animal models of ms. we investigated the status of cannabinoid cb1 and cb2 receptors and fatty acid amide hydrolase (faah) enzyme in brain tissue samples obtained from ms patients. |
2007-03-19 |
2023-08-12 |
human |
| Cristina Benito, Juan Pablo Romero, Rosa María Tolón, Diego Clemente, Fabián Docagne, Cecilia J Hillard, Camen Guaza, Julián Romer. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 9. 2007-03-19. PMID:17329437. |
as seen for other neuroinflammatory conditions, selective glial expression of cannabinoid cb1 and cb2 receptors and faah enzyme is induced in ms, thus supporting a role for the endocannabinoid system in the pathogenesis and/or evolution of this disease. |
2007-03-19 |
2023-08-12 |
human |
| Yoshitomo Suhara, Saori Oka, Atsushi Kittaka, Hiroaki Takayama, Keizo Waku, Takayuki Sugiur. Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorganic & medicinal chemistry. vol 15. issue 2. 2007-03-13. PMID:17110113. |
2-arachidonoylglycerol (2-ag (1)) is an endogenous ligand for the cannabinoid receptors (cb1 and cb2). |
2007-03-13 |
2023-08-12 |
Not clear |
| Yoshitomo Suhara, Saori Oka, Atsushi Kittaka, Hiroaki Takayama, Keizo Waku, Takayuki Sugiur. Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorganic & medicinal chemistry. vol 15. issue 2. 2007-03-13. PMID:17110113. |
notably, these structural analogs of 2-arachidonoylglycerol exhibited only weak agonistic activities toward either the cb1 receptor or the cb2 receptor, which is in good contrast to 2-arachidonoylglycerol which acted as a full agonist at these cannabinoid receptors. |
2007-03-13 |
2023-08-12 |
Not clear |
| Yoshitomo Suhara, Saori Oka, Atsushi Kittaka, Hiroaki Takayama, Keizo Waku, Takayuki Sugiur. Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorganic & medicinal chemistry. vol 15. issue 2. 2007-03-13. PMID:17110113. |
these results clearly indicate that the structure of 2-arachidonoylglycerol is strictly recognized by the cannabinoid receptors (cb1 and cb2) and provide further evidence that the cannabinoid receptors are primarily the intrinsic receptors for 2-arachidonoylglycerol. |
2007-03-13 |
2023-08-12 |
Not clear |
| Jürg Gertsch, Stefan Raduner, Karl-Heinz Altman. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. Journal of receptor and signal transduction research. vol 26. issue 5-6. 2007-03-06. PMID:17118807. |
new natural noncannabinoid ligands for cannabinoid type-2 (cb2) receptors. |
2007-03-06 |
2023-08-12 |
human |
| Jürg Gertsch, Stefan Raduner, Karl-Heinz Altman. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. Journal of receptor and signal transduction research. vol 26. issue 5-6. 2007-03-06. PMID:17118807. |
constitute a new class of cannabinomimetics, which specifically engage and activate the cannabinoid type-2 (cb2) receptors. |
2007-03-06 |
2023-08-12 |
human |
| Jürg Gertsch, Stefan Raduner, Karl-Heinz Altman. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. Journal of receptor and signal transduction research. vol 26. issue 5-6. 2007-03-06. PMID:17118807. |
cannabinoid type-1 (cb1) and cb2 receptors belong to the family of g protein-coupled receptors and are the primary targets of the endogenous cannabinoids n-arachidonoyl ethanolamine and 2-arachidonoyl glyerol. |
2007-03-06 |
2023-08-12 |
human |
| Christine Börner, Volker Höllt, Walter Sebald, Jürgen Krau. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. Journal of leukocyte biology. vol 81. issue 1. 2007-03-05. PMID:17041005. |
effects of cannabinoids (cbs) are mediated by two types of receptors, cb1 and cb2. |
2007-03-05 |
2023-08-12 |
Not clear |
| Gabriele Murineddu, Paolo Lazzari, Stefania Ruiu, Angela Sanna, Giovanni Loriga, Ilaria Manca, Matteo Falzoi, Christian Dessì, Maria M Curzu, Giorgio Chelucci, Luca Pani, Gérard A Pinn. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. Journal of medicinal chemistry. vol 49. issue 25. 2007-02-23. PMID:17149879. |
synthesis and biological evaluation of analogues of the robust and selective cb2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-n-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. |
2007-02-23 |
2023-08-12 |
human |
| Yoshifumi Ueda, Naoki Miyagawa, Korekiyo Wakitan. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life sciences. vol 80. issue 5. 2007-02-20. PMID:17055000. |
involvement of cannabinoid cb2 receptors in the ige-mediated triphasic cutaneous reaction in mice. |
2007-02-20 |
2023-08-12 |
mouse |
| Yoshifumi Ueda, Naoki Miyagawa, Korekiyo Wakitan. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life sciences. vol 80. issue 5. 2007-02-20. PMID:17055000. |
involvement of cannabinoid cb2 receptors in the ige-mediated cutaneous reaction was investigated. |
2007-02-20 |
2023-08-12 |
mouse |
| Yoshifumi Ueda, Naoki Miyagawa, Korekiyo Wakitan. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life sciences. vol 80. issue 5. 2007-02-20. PMID:17055000. |
in contrast, cannabinoid cb2 receptor-deficient mice failed to exhibit the obvious triphasic ear swelling observed in wild-type mice. |
2007-02-20 |
2023-08-12 |
mouse |
| Yoshifumi Ueda, Naoki Miyagawa, Korekiyo Wakitan. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life sciences. vol 80. issue 5. 2007-02-20. PMID:17055000. |
oral administration of cannabinoid cb2 receptor antagonist/inverse agonists [n-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide] (jte-907) and {n-[(1s)-endo-1,3,3-trimethylbicyclo[2,2,1]heptan-2yl]5-(4-chloro-3-methyl-phenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide} (sr144528) at doses of 0.1-10 mg/kg significantly and dose-dependently suppressed all three phases of ear swelling in balb/c mice. |
2007-02-20 |
2023-08-12 |
mouse |
| Yoshifumi Ueda, Naoki Miyagawa, Korekiyo Wakitan. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life sciences. vol 80. issue 5. 2007-02-20. PMID:17055000. |
these results suggest that cannabinoid cb2 receptors are involved in induction of the triphasic cutaneous reaction mediated by ige, and that cannabinoid cb2 receptor antagonist/inverse agonists may serve as anti-allergic agents in the treatment of allergic dermatitis. |
2007-02-20 |
2023-08-12 |
mouse |
| A Scutt, E M Williamso. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcified tissue international. vol 80. issue 1. 2007-02-20. PMID:17205329. |
cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via cb2 receptors. |
2007-02-20 |
2023-08-12 |
Not clear |
| Leos Landa, Karel Slais, Alexandra Sulcov. Impact of cannabinoid receptor ligands on behavioural sensitization to antiaggressive methamphetamine effects in the model of mouse agonistic behaviour. Neuro endocrinology letters. vol 27. issue 6. 2007-02-15. PMID:17187025. |
the present study was focused on a possible sensitisation to antiaggressive effect of methamphetamine and cross-sensitization to this effect after repeated pre-treatment with cannabinoid cb1 and cb2 receptor ligands with different intrinsic activity (cb1 agonist methanandamide, cb2 agonist jwh 015, and cb1 antagonist am 251). |
2007-02-15 |
2023-08-12 |
mouse |
| C Velez-Pardo, M Jimenez Del Ri. Avoidance of Abeta[(25-35)] / (H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53. Medicinal chemistry (Shariqah (United Arab Emirates)). vol 2. issue 5. 2007-01-30. PMID:17017986. |
the present study shows that cp55,940 (a cb1 and cb2 agonist) and jwh-015 (a cb2 agonist) protect and rescue peripheral blood lymphocytes (pbl) from (10 microm) abeta[(25-35)] and (50 microm) h(2)o(2)-induced apoptosis by two alternative mechanisms: (1) receptor-independent pathway, as demonstrated by no-dihydrorhodamine oxidation into fluorescent rhodamine 123 (r-123) as a result of cannabinoid inhibition of abeta-generated h(2)o(2); (2) receptor-dependent pathway through nf-kappab activation and p53 down regulation involving phosphoinositide 3-kinase (pi-3k), as demonstrated by using either (25 microm) ly294002 (a pi-3k inhibitor), (50 nm) pifithrin-alpha (pft, a specific p53 inhibitor) or by using immunocytochemistry detection of nf-kappab and p53 transcription factors activation. |
2007-01-30 |
2023-08-12 |
Not clear |